<DOC>
	<DOCNO>NCT00369343</DOCNO>
	<brief_summary>Desvenlafaxine succinate ( DVS ) potent selective serotonin norepinephrine reuptake inhibitor ( SNRI ) . The sustained-release ( SR ) formulation , DVS SR , study development program treatment major depressive disorder ( MDD ) , vasomotor symptom ( VMS ) associate menopause , pain associated peripheral diabetic neuropathy , well treatment fibromyalgia syndrome . This study investigate safety , efficacy , tolerability DVS SR woman MDD peri- postmenopausal .</brief_summary>
	<brief_title>Study Evaluating Desvenlafaxine Succinate Sustained Release ( DVS SR ) Versus Placebo Peri- Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Peri postmenopausal woman age 40 70 year , inclusive . A primary diagnosis MDD , single recurrent episode , without psychotic feature use modified International Neuropsychiatric Interview ( MINI ) . MontgomeryAsberg Depression Rating Scale ( MADRS ) total score &gt; = 22 screen baseline visit . Use oral estrogen , progestin , androgen , Selective Estrogen Receptor Modulator ( SERM ) contain drug product 8 week baseline . Current ( within 12 month ) psychoactive substance abuse dependence ( include alcohol ) , manic episode , posttraumatic stress disorder , obsessivecompulsive disorder , lifetime diagnosis bipolar psychotic disorder . A history active presence clinically important medical disease . Additional criterion apply .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>vasomotor symptom</keyword>
	<keyword>menopause</keyword>
	<keyword>diabetic neuropathy</keyword>
	<keyword>fibromyalgia</keyword>
</DOC>